2021 annual financial data
Lyell Immunopharma 2021 Operating cash flow margin
Direct answer
Operating cash flow margin was -1,185.44%.
Operating income was -214,776,000 USD and net income was -250,219,000 USD.
Operating cash flow was -126,249,000 USD.
Get free Lyell Immunopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 10,650,000 USD
- Operating income
- -214,776,000 USD
- Net income
- -250,219,000 USD
- Operating cash flow
- -126,249,000 USD